Florian Brand

Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...

Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.  In numbers: Cash, cash equivalents and short-term investments totaled $209.0 million as of Sept. 30, compared...

Clinical stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) technology, with topline results expected in the first half of 2023....

Kratom grows in several Asian countries and has been traditionally used by local communities as a natural home remedy for pain, depression and addiction. Now, several psychedelics companies are developing substances based on this plant and several US states have already enacted legislation that...

Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE: HTGC). The company...

Atai Life Sciences N.V. (NASDAQ: ATAI) recently filed a registration statement with the Securities and Exchange Commission for capital raise of up to $300 million through the issuance of common shares, debt securities, warrants and units. As explained by Jason Najum on Microdose, by using a...

Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022. “We made great progress in the first quarter on our mission to achieve...

Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in...

MAPS Gets $30M In Funds To Conclude MDMA Research The Multidisciplinary Association for Psychedelic Studies recently completed a fundraising of $30 million. The funds will help MAPS finish the NGO’s ongoing research for MDMA-assisted psychotherapy in the treatment of post-...

With a growing public acceptance of cannabis in society, there's a natural instinct to wonder about the possible health benefits and market potential of other still-illegal substances. “To me, all the psychedelic stuff, it's just prohibition 2.0,” Bruce Linton, cannabis...